MedPath

GENENTECH INC

GENENTECH INC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

108

Active:90
Completed:5

Trial Phases

4 Phases

Phase 1:82
Phase 2:4
Phase 3:6
+1 more phases

Drug Approvals

13

NMPA:5
CANADA:3
FDA:2

Drug Approvals

Trastuzumab Injection

Product Name
赫赛汀
Approval Number
国药准字J20170037
Approval Date
May 11, 2017
NMPA

Trastuzumab Injection

Product Name
赫赛汀
Approval Number
J20170037
Approval Date
May 11, 2017
NMPA

Trastuzumab Injection

Product Name
赫赛汀
Approval Number
S20160056
Approval Date
Dec 9, 2016
NMPA

Trastuzumab Injection

Product Name
注射用曲妥珠单抗
Approval Number
S20150068
Approval Date
Dec 23, 2015
NMPA

Trastuzumab Injection

Product Name
赫赛汀
Approval Number
S20150067
Approval Date
Dec 23, 2015
NMPA

Clinical Trials

Distribution across different clinical trial phases (95 trials with phase data)• Click on a phase to view related trials

Phase 1
82 (86.3%)
Phase 3
6 (6.3%)
Phase 2
4 (4.2%)
phase_1_2
2 (2.1%)
Phase 4
1 (1.1%)
No trials found

News

Metformin Shows Potential Survival Benefit in HER2-Positive Breast Cancer Patients

A comprehensive scoping review of 40 clinical trials published in BMC Cancer reveals that metformin may modestly increase pathologic complete response rates in HER2-positive breast cancer patients when added to standard treatment regimens.

RESTEM Receives FDA Orphan Drug Designation for Stem Cell Therapy in Polymyositis Treatment

RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.